Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McNeil labeling deferrals

This article was originally published in The Tan Sheet

Executive Summary

Firm receives six-month deferral from OTC labeling compliance date for 10-count vials of two Tylenol SKUs and two-count pouches of Motrin IB, Tylenol and Imodium products. In Dec. 21 letter, FDA says product labeling must comply with "Drug Facts" requirements by Nov. 16. J&J division originally sought eight-month deferral for vials to allow time for new wrap-around labeling. In November, McNeil requested additional six months to implement "booklet style" labeling on five pouch products (1"The Tan Sheet" Dec. 10, 2001, p. 3)...

You may also be interested in...

McNeil “Drug Facts” Booklet Pouch Labeling Proposed For Two-Count Sizes

McNeil Consumer Healthcare is requesting a six-month deferral from the OTC labeling final rule requirements to implement "booklet pouch" labeling for two-count sizes of five products

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts